Cannabis-Derived Phytocannabinoid Composition for Cytokine Storm Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for COVID-19 and other viral infections, such as cytokine storm syndrome, lack effective strategies to modulate immune responses and reduce inflammation, particularly in the respiratory system, where cytokine storms can lead to severe complications like ARDS.

Innovation Solution

A cannabis-derived fraction comprising at least 80% CBD, with additional CBG and THCV, is administered to activate macrophages and reduce inflammation in lung epithelial cells, offering a therapeutic approach to manage infectious diseases and cytokine storms by modulating cytokine levels and macrophage activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for COVID-19 and viral infections are used, then existing therapeutic protocols are maintained, but effective strategies to modulate immune responses and reduce inflammation are lacking

Engineering Contradiction:

Improveeffectiveness of immune response modulationVSAvoidability to modulate cytokine levels and macrophage activity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent employs a composite phytocannabinoid composition containing multiple cannabinoids (CBD, CBG, THCV) in specific ratios to achieve synergistic immune modulation effects that individual compounds cannot accomplish alone, thereby resolving the contradiction between reliable immune response modulation and adaptability to different disease stages

Inventive Principle:

Principle #40Composite materials

2Object-affected harmful factors

If pro-inflammatory cytokine secretion is reduced, then inflammation in lung epithelial cells decreases, but macrophage activation may be insufficient to eliminate the virus

Engineering Contradiction:

Improvepro-inflammatory cytokine secretion from lung epithelial cellsVSAvoidmacrophage activation for virus elimination

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies opposite actions to different cell types: it suppresses pro-inflammatory cytokine secretion from lung epithelial cells while simultaneously activating macrophages to produce cytokines and enhance phagocytosis, thereby resolving the contradiction between reducing harmful inflammation and maintaining effective virus elimination

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The composition exhibits differential effects on different cell types - it selectively reduces inflammation in lung epithelial cells while selectively activating macrophages, demonstrating local quality differentiation to resolve the contradiction between reducing harmful inflammation and maintaining effective immune response

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20230277564A1Cannabinoidal compositions for the treatment of disease

Publication Date: 2023.09.07 THE STATE OF ISRAEL MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT

AI summary

Cannabinoidal compositions for the treatment of disease are provided. Accordingly, there is provided a method of treating a disease that can benefit from activating macrophages comprising administering to the subject a therapeutically effective amount of a composition comprising a cannabis derived fraction comprising phytocannabinoids, wherein said phytocannabinoids comprise at least 80% CBD and at least one of CBG and THCV. Also provided is a method of treating a cytokine storm comprising administering to the subject a therapeutically effective amount of a synthetic composition comprising phytocannabinoids, wherein said phytocannabinoids comprise at least 80% CBD and at least one of CBG and THCV.